Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Revenue (2024)

Zentalis Pharmaceuticals has reported Revenue over the past 1 years, most recently at $26.9 million for Q4 2024.

  • For Q4 2024, Revenue changed N/A year-over-year to $26.9 million; the TTM value through Sep 2025 reached $26.9 million, down 33.76%, while the annual FY2024 figure was $67.4 million, N/A changed from the prior year.
  • Revenue for Q4 2024 was $26.9 million at Zentalis Pharmaceuticals, down from $40.6 million in the prior quarter.
  • Over five years, Revenue peaked at $40.6 million in Q1 2024 and troughed at $26.9 million in Q4 2024.